+4,601.6%
SNDK vs GSK
+42.4%
+4,559.2%
-56.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.1% | -1.0% | -3.0% | -4.0% |
| 7D | +8.8% | -5.4% | +14.3% | +9.0% |
| 30D | +33.2% | -4.6% | +37.8% | +33.2% |
| 3M | +3.0% | -5.1% | +8.1% | +2.2% |
| 6M | +173.5% | -11.4% | +184.9% | +178.6% |
| YTD | +613.0% | +0.7% | +612.3% | +579.9% |
| 1Y | +2,189.8% | +23.0% | +2,166.7% | +1,853.3% |
| All | +4,601.6% | +42.4% | +4,559.2% | +3,507.4% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling